Assessment of the response of patients with Crohn's disease to biological therapy using new non-invasive markers: Lactoferrin and calprotectin;Avaliação da resposta de pacientes com doença de crohn ao tratamento biológico, através de novos marcadores não invasivos: Lactoferrina e calprotectina

Arquivos de Gastroenterologia

Volumn 50, Issue 2, 2013, Pages 130-137

  Nogueira, Islaine Martins ^a   Miszputen, Sender Jankiel ^a   Ambrogini, Orlando ^a   Artigiani Neto, Ricardo ^a   Carvente, Cláudia Teresa ^a   Zanon, Maria Ivani ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Biological markers; Biological therapy; Crohn disease

Indexed keywords

CALGRANULIN; INFLIXIMAB; LACTOFERRIN;

ARTICLE; BIOLOGICAL THERAPY; CLINICAL ARTICLE; COLONOSCOPY; COMPARATIVE STUDY; CROHN DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE;

ADULT; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BIOLOGICAL THERAPY; BIOPSY; C-REACTIVE PROTEIN; COLONOSCOPY; CROHN DISEASE; FECES; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; LACTOFERRIN; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84880070444     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/S0004-28032013000200022     Document Type: Article

References (35)

1. Angriman I, Scarpa M, D'Incà R, Basso D, Ruffolo C, Polese L, Sturniolo GC, D'amico DF, Plebani M. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta. 2007;381:63-68.
2. Benevento G, Avellini C, Terrosu G, Geraci M, Lodolo I, Sorrentino D. Diagnosis and assessment of Crohn's disease: the present and the future. Expert Rev Gastroenterol Hepatol. 2010;4:757-766.
3. Buderus S, Boone J, Lyerly D, Lentze MJ. Fecal Lactoferrin: a new parameter to monitor infiximab therapy. Dig Dis Sci. 2004;49:1036-1039.
4. Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE. Fecal calpro-tectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33:14-22.
5. Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, Ricchiuti A, Marchi S, Bottai M. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005;54:364-368.
6. Cottone M, Criscuol V. Infiximab to treat Crohn's disease: an update. Clin Exp Gastroenterol. 2011;4:227-238.
7. D'Incà R, Dal Pont E, Di Leo V, Ferronato A, Fries W, Vettorato MG, Martines D, Sturniolo GC. Calprotectin and lactoferrin in the assessmentof intestinal inflammation and organic disease. Int J Colorectal Dis. 2007;22:429-437.
8. Fell JM. Update of the management of inflammatory bowel disease. Arch Dis Child. 2012;97:78-83.
9. Freeman HJ. Long-term natural history of Crohn's disease. World J Gastroen-terol. 2009;15:1315-1318.
10. Gaya DR, Mackenzie JF. Faecal calprotectin: a bright future for assessing disease activity in Crohn's disease. QJM. 2002;95:557-558.
11. Gaya DR, Lyon TD, Duncan A, Neilly JB, Han S, Howell J, Liddell C, Stanley AJ, Morris AJ, Mackenzie J. F. Faecal calprotectin in the assessment of Crohn's disease activity. QJM. 2005;98:435-441.
12. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal cal-protectin as a biological marker in inflammatory bowel disease. Dig Liver Dis. 2009;41:56-66.
13. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
14. Jensen MD, Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn's-disease affecting the small bowel and colon. Scand J. Gastroenterol. 2011;46:694-700.
15. Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003;98:1309-1314.
16. Kayazawa M, Saitoh O, Kojima K, Nakagawa K, Tanaka S, Tabata K, Matsuse R, Uchida K, Hoshimoto M, Hirata I, Katsuk. Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol. 2002;97:360-369.
17. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140:1817-1826.
18. Limburg PJ, Ahlquist DA, Sandborn WJ, Mahoney DW, Devens ME, Harrington JJ, Zinsmeister AR. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastro-enterol. 2000;95:2831-2837.
19. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: A prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30:983-989.
20. Naber AH, de Jong DJ. Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials. Neth J Med. 2003;61:105-110.
21. Peyrin-Biroulet L, Deltenre P, Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644-653.
22. Røseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neu-trophil dominating protein calprotectin in feces: a methodologic study. Scand J Gastroenterol. 1992;27:793-798.
23. Røseth AG, Schimidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker Protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999;34:50-54.
24. Røseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004;39:1017-1020.
25. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56:453-455.
26. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Löfberg R, Modigliani R, Present DH, Rutgeerts P, Schölmerik J, Stange EF, Sutherland LR. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterol. 2002;122:512-530.
27. Sipponen T, Kärkkäinen P, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Correlation of a faecal calprotectin and lactoferrin with an endo-scopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221-1229.
28. Sipponen T, Savilahti E, Kärkkäinen P, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Infamm Bowel Disease. 2008;14:1392-1398.
29. Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther. 2003;17:11-17.
30. Sutherland AD, Gearry RB, Frizelle FA. Review of fecal biomarkers in infam-matory bowel disease. Dis Colon Rectum. 2008;51:1283-91.
31. Tibble JA, Teahon K, Thjodleifssonb, Roseth A, Sigthorsson G, Bridger S, Foster R, Sherwood R Fagerhol M, Bjarnason I. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000;47:506-13.
32. Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol. 2001;7:460-465.
33. Vieira A, Fang CB, Rolim EG, Klug WA, Steinwurz F, Rossini LG, Candelária PA. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Notes. 2009;2:221.
34. Walker TR, Land ML, Kartashov A, Saslowsky TM, Lyerly DM, Boone JH, Rufo PA. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroen-terol Nutr. 2007;44:414-22.
35. Walsh A, Mabee J, Trivedi K. Inflammatory bowel disease. Prim Care Clin. 2011;38:415-432.